In prostate cancer, radiolabelled antibodies like 177Lu-PSMA-617 have emerged as potent tools, capitalizing on the overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer cells [98], as depicted in Fig. 3. The gene discussed is FOLH1; the disease is prostate carcinoma.